Pejmon Pashai

Pejmon Pashai focuses his practice on intellectual property litigation for innovative biotechnology and pharmaceutical companies, primarily patent and trade secret litigation for gene therapies, novel botulinum toxin type A products, small molecules, and drug delivery devices. Mr. Pashai has extensive experience in cases arising under the Hatch-Waxman Act and pre-BPCIA diligence. He is involved in all aspects of litigation, including pre-litigation due diligence, fact discovery, expert discovery, fact witness and expert depositions, motions practice, and trial preparation. Mr. Pashai has also published and presented at international conferences on his research in the field of arterial chemoreception.

Prior to joining Dechert, Mr. Pashai was an attorney in the Washington, D.C. office of an international law firm.